The global osteoporosis drugs market is expected to reach USD 16.3 billion by 2025, according to a new study by Grand View Research, Inc. An upsurge rise in the unhealthy lifestyle adoption has resulted in aggravation and increase in the prevalence of osteoporosis which is presumed to propel the osteoporosis drugs market during the forecast period.
In
addition, growing number of patent expiries is fueling the high clinical
urgency to use generic versions of the established drugs, which is presumed to
fuel generic osteoporosis drugs market during the forecast period. The
aforementioned factors cumulatively are slated to present the with high
potential growth opportunities over the coming years.
Furthermore,
rising number of initiatives to increase the awareness levels pertaining to
osteoporosis care amongst the patients as well as the physicians is expected to
widen the osteoporosis market growth potential during the forecast period. For
instance, National Osteoporosis Foundation (NOF), a healthcare organization
responsible for National Bone Health Alliance and Fracture Liaison Service
(FLS) care coordination programs that focuses on elevating awareness levels as
well as provides training to healthcare professionals
Full Research Report On Osteoporosis Drugs Market Visit Here:
https://www.grandviewresearch.com/industry-analysis/osteoporosis-drug-market
Further key
findings from the study suggest:
- Branded drugs held the
dominant share of the product segment in 2015. The dominant share can be
attributed to extensive utilization of bisphosphates, rank ligand
inhibitors for the treatment of osteoporosis, possessing high efficacy
- Generics are expected to
witness at a lucrative CAGR owing to consistent patent expiries over the
coming years as well as high clinical urgency for inexpensive medication
in the emerging economies
- In 2015, North America
accounted for the largest share in the global osteoporosis drugs market
owing to the presence of established companies extensively involved in the
commercialization of branded therapeutics
- Asia Pacific is anticipated
to grow at an exponential CAGR as a consequence of favorable government
initiatives promoting information pertaining to osteoporosis care
- The key participants are
employing sustainability strategies promoting the adoption of osteoporosis
therapeutics to gain competitive advantage. For instance, Actavis Inc.
announced to acquire Warner Chilcott PLC in order to widen their product
portfolio
Request a Sample Copy of the Report @
https://www.grandviewresearch.com/industry-analysis/osteoporosis-drug-market/request/rs1
Grand View Research has segmented
the osteoporosis drugs market on the basis of product and region:
Global Osteoporosis
Product Outlook (Revenue, USD Million, 2014 – 2025)
- Branded
- Bisphosphonates
- Parathyroid Hormone Therapy
- Calcitonin
- Selective Estrogen Inhibitors
Modulator(SERM)
- Rank Ligand Inhibitors
- Others
- Generics
Osteoporosis Drugs
Regional Outlook (Revenue, USD Billion, 2014 – 2025)
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- Asia Pacific
- Japan
- China
- India
- Latin America
- Mexico
- Brazil
- MEA
- South Africa
About Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, we offer
market intelligence studies ensuring relevant and fact-based research across a
range of industries, from technology to chemicals, materials and healthcare.
For more info visit @ https://www.grandviewresearch.com